Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer

Pfizer's ($PFE) Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond. But Pfizer may need that head start and more to stay ahead of a pair of up-and-comers currently in its rivals' pipelines. More from FiercePharmaMarketing